Overview
Astragalus membranaceus is a traditional Chinese medicinal herb with over 2,000 years of documented use in supporting health and longevity. Modern scientific research has identified its active constituents—polysaccharides, saponins (astragalosides), and flavonoids—as responsible for its diverse therapeutic effects. This comprehensive guide examines the current evidence for astragalus across multiple health domains, from immune function to athletic performance.
What Is Astragalus?
Astragalus membranaceus belongs to the Fabaceae (legume) family and is traditionally used as a general health tonic. In contemporary wellness protocols, it's valued for its adaptogenic properties and potential to support immune function, cardiovascular health, and cellular aging processes. The herb is available as a dried root powder, extract, or standardized supplement formulation, with oral ingestion being the standard route of administration.
Traditional Use vs. Modern Evidence
While traditional Chinese medicine has long recognized astragalus as a qi (energy) tonic for fatigue and weakness, modern research has shifted focus to measurable biomarkers: immune cell counts, inflammatory cytokines, telomere length, and cardiac function. This transition from historical use to evidence-based evaluation reveals both promising mechanisms and current gaps in human clinical data.
How It Works: Mechanism of Action
Astragalus exerts its health effects through multiple interconnected biological pathways, making it a compound of significant mechanistic interest.
Immune Activation
Astragalus polysaccharides stimulate both innate and adaptive immunity by activating macrophages, natural killer cells, and T-lymphocytes. This immune enhancement partly occurs through Toll-like receptor (TLR) signaling pathways, triggering downstream immune responses. In cancer and chronic disease contexts, these polysaccharides increase circulating T-cell populations and improve immune cell ratios—effects documented in multiple human meta-analyses.
Telomerase Activation and Cellular Aging
Astragaloside IV and its derivative, cycloastragenol, uniquely activate telomerase (hTERT), the enzyme responsible for maintaining telomeres—the protective caps on chromosomes. By slowing telomere shortening, astragalus may reduce cellular senescence and theoretically extend replicative lifespan. However, human evidence shows telomere elongation alone does not necessarily translate to improved physical function.
Antioxidant and Anti-Inflammatory Effects
Astragalus exhibits antioxidant activity by upregulating Nrf2 pathway enzymes, reducing reactive oxygen species (ROS) in cells. Additionally, it exerts mild anti-inflammatory action by downregulating NF-κB signaling, a key driver of chronic inflammation. These mechanisms are particularly relevant in conditions involving oxidative stress and tissue damage.
Evidence by Health Goal
The following sections organize astragalus research by therapeutic application, with evidence tier ratings and specific quantitative findings.
Immune Support — Tier 3 (Probable Efficacy)
Key Finding: A meta-analysis of 31 randomized controlled trials (n=2,648 participants) found that astragalus polysaccharides increased CD3+ T-cell count by 8.79 cells/μL (95% CI 6.15–11.43, p<0.01) and CD4+ T-cell count by 7.94 cells/μL (95% CI 5.27–10.61, p<0.01) in cancer patients. The CD4+/CD8+ ratio improved by 0.40 (95% CI 0.28–0.52, p<0.01), and treatment groups showed a 30% relative increase in objective response rates.
Strength of Evidence: While these data are encouraging, most human evidence originates from small, non-blinded trials conducted in China. Large-scale, independently replicated randomized controlled trials with Western populations are lacking, limiting generalizability.
Energy and Fatigue Reduction — Tier 3 (Probable Efficacy)
Cancer-Related Fatigue: A meta-analysis of 8 randomized controlled trials demonstrated significant fatigue reduction with a standardized mean difference (SMD) of -1.63 (95% CI [-1.90, -1.36], p<0.00001). Quality of life improved with an SMD of 0.86 (p=0.01).
Post-Stroke Fatigue: Analysis of 16 randomized controlled trials (n=1,222 total) showed that adjuvant astragalus therapy decreased fatigue severity on multiple scales: Fatigue Severity Scale, Fugl-Meyer, and Visual Analogue Scale.
Exercise Performance: In 80 patients with chronic fatigue, a herbal complex containing astragalus increased maximal exercise time to exhaustion (p=0.003), distance to exhaustion (p=0.003), and VO2 max (p=0.039).
Heart Health — Tier 3 (Probable Efficacy)
Myocardial Protection: A meta-analysis of 28 randomized controlled trials (n=2,522) demonstrated that astragalus significantly reduced serum myocardial enzymes and cardiac troponin I in viral myocarditis patients, with improved clinical treatment efficiency (p<0.05) and no significant increase in adverse reactions.
Post-Infarction Recovery: In animal models of myocardial infarction, astragaloside IV improved ventricular remodeling, reduced myocardial fibrosis area, decreased cardiomyocyte cross-sectional area, and reduced expression of fibrosis-related proteins.
Anti-Inflammation — Tier 3 (Probable Efficacy)
Cytokine Reduction: A meta-analysis of 19 randomized controlled trials (n=1,094 participants) found that astragalus reduced pro-inflammatory cytokines (IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ) with an SMD of -2.8765 (95% CI: -3.2385 to -2.5145, p<0.0001).
Mechanism Validation: In cultured immune cells treated with oxygen-glucose deprivation and reperfusion injury, astragalus polysaccharides decreased IL-1β by 55% and IL-6 by 47%, while increasing IL-10 by 106% (all p<0.001).
Joint Health — Tier 3 (Probable Efficacy)
Knee Pain: A 28-day double-blind randomized controlled trial (n=45) showed significant knee pain reduction, with VAS (Visual Analogue Scale) scores dropping from 6.7±0.5 to 1.2±0.6 (p<0.0001). Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), stair climb test, and knee range of motion all significantly improved (p<0.0001).
Limitation: This efficacy is based on a single well-designed human trial; additional independent replication is needed.
Athletic Performance and Recovery — Tier 3 (Probable Efficacy)
Amino Acid Absorption: In 30 healthy adults, astragalus saponins increased valine absorption by 6.67% acutely and 14.07% after 4 weeks, with pronounced effects in older adults (60–80 years: 12.74% increase in total essential amino acids).
Exercise-Induced Muscle Damage: Astragaloside supplementation (4 mg/day × 7 days) reduced serum muscle damage markers (creatine kinase, lactate dehydrogenase, myoglobin) at 1–3 days post-exercise compared to placebo, with muscular strength returning to baseline 2 days earlier than placebo (n=11, double-blind randomized controlled trial).
Muscle Growth and Atrophy Prevention — Tier 2 (Plausible Efficacy)
Denervation-Induced Atrophy: Astragaloside IV significantly inhibited reduction in tibialis anterior muscle mass and cross-sectional area in denervated mice. It reduced expression of MAFbx and MuRF1 (muscle-specific ubiquitin ligases) and FoxO3a transcription factor in muscle tissue.
Human Evidence Gap: Only one human study directly examined muscle-related outcomes; human efficacy for muscle hypertrophy or strength gains remains unestablished.
Injury Recovery — Tier 2 (Plausible Efficacy)
Spinal Cord Injury: A meta-analysis of 16 rat spinal cord injury studies (n=996 animals) found that astragalus membranaceus extract produced a mean functional motor recovery improvement of 3.68 points (95% CI 2.74–4.62), with best results at doses >20 units and treatment duration <14 days.
Human Evidence: Three randomized controlled trials exist with small sample sizes and short follow-up periods, making efficacy plausible but not yet conclusively proven in humans.
Fat Loss — Tier 2 (Plausible Efficacy)
Animal Models: Formononetin from astragalus membranaceus increased UCP1 expression in cultured mouse adipocytes and reduced weight gain in diet-induced obese mice with higher energy expenditure versus untreated controls.
Human Evidence: A 12-week randomized controlled trial (n=44) using a botanical extract combining creatine, ginseng, and astragalus (CrBE) produced significantly greater body fat loss and bench press strength gains compared to creatine alone, though absolute fat loss percentages were not reported.
Skin and Hair Health — Tier 2 (Plausible Efficacy)
Antioxidant Protection: Astragaloside IV at 50 μM significantly reduced intracellular ROS and malondialdehyde content while increasing superoxide dismutase (SOD) activity in UVB-exposed human keratinocytes. Pretreatment at doses of 10–150 μM increased cell viability.
Clinical Outcomes: A meta-analysis identified astragalus compounds promoting collagen synthesis, ROS reduction, mitochondrial preservation, and telomere elongation, with clinical trials showing improvements in skin hydration, tone, and wrinkle reduction.
Cognition and Neuroprotection — Tier 2 (Plausible Efficacy)
Stroke Protection: In rat models of middle cerebral artery occlusion and reperfusion (MCAO/R), astragaloside IV and herbal combinations reduced infarct volume and improved neurological scores, with molecular evidence of SIRT7/VEGFA pathway activation and angiogenesis promotion.
Human Evidence: One small randomized controlled trial (n=83) showed improved neurological outcomes in subarachnoid hemorrhage patients, but cognition was not directly measured.
Longevity and Cellular Aging — Tier 2 (Plausible Efficacy)
Telomere Elongation: A meta-analysis of 8 randomized controlled trials (n=750) using TA-65 (a cycloastragenol product) demonstrated moderate telomere elongation (SMD=0.47, 95% CI: 0.31–0.62, p<0.00001), with amplified effects in adults older than 60 years (SMD=0.63 versus 0.36; p=0.03).
Functional Limitations: However, telomere elongation with TA-65 did not translate to improvements in frailty metrics (SPPB, grip strength, 6-minute walk test: SMD=0.09, p=0.15) or inflammatory markers (CRP/IL-6: SMD=-0.11, p=0.07).
Gut Health — Tier 2 (Plausible Efficacy)
Microbiota Modulation: In diabetic rats, astragalus mongholicus polysaccharides increased beneficial bacteria (Muribaculaceae, Ruminococcus_1, Lachnoclostridium) with negative correlation between microbiota composition and serum kidney markers (BUN, creatinine, uric acid).
Intestinal Barrier: Astragaloside IV in colitis-induced mice significantly improved intestinal barrier integrity via tight junction protein upregulation and reduced pro-inflammatory cytokine expression through SIRT1/PGC-1α/NF-κB pathway modulation.
Human Evidence Gap: Only 3 human randomized controlled trials exist, and none specifically measure gut health endpoints with validated metrics.
Liver Health — Tier 2 (Plausible Efficacy)
Hepatoprotection: Astragaloside IV (40–80 mg/kg) reduced cisplatin-induced liver injury and hepatocyte ferroptosis in mice by modulating ferroptosis-dependent pathways. Isoastragaloside I ameliorated bile duct ligand-induced cholestatic liver disease in mice by regulating bile acid metabolism and restoring intestinal barrier function.
Human Evidence: Only one small randomized controlled trial and two observational studies exist, making efficacy in humans unproven.
Hormonal Balance and Sexual Health — Tier 3 (Probable Efficacy)
Benign Prostatic Hyperplasia: In an 84-participant randomized controlled trial, astragalus improved the International Index of Erectile Function (IIEF) total score, erectile function, sexual desire, and hormone levels (testosterone/dihydrotestosterone) after 12 weeks (p<0.05).
Menopausal Symptoms: In approximately 100 postmenopausal women, a combination of Rubus coreanus and astragalus extract decreased Kupperman index and Menopause Rating Scale scores versus placebo after 12 weeks with no serious adverse effects.
Renal Dysfunction: In 36 chronic renal failure patients, astragalus-containing formula decreased sexual dysfunction symptom scores from 12.5±2.91 to 5.58±4.68 (p<0.001).
Mood and Stress — Tier 1 (Insufficient Evidence)
Evidence Status: Astragalus has not been studied for mood or stress outcomes in rigorous human trials. While traditional use and one review mention 'anti-stress' properties as a general claim, no empirical mood, anxiety, depression, or stress-related measurement data exists in the scientific literature.
Sleep — Tier 2 (Plausible Efficacy)
Animal Evidence: Astragalus polysaccharide significantly attenuated sleeping disorders in aging fruit flies via JAK-STAT, Toll, and IMD signaling pathway modulation.
Human Evidence: No human randomized controlled trials specifically testing astragalus for sleep have been identified. Human efficacy remains unproven.